Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinson's Disease

Int J Mol Sci. 2020 Nov 17;21(22):8666. doi: 10.3390/ijms21228666.

Abstract

The primary pathogenesis associated with Parkinson's disease (PD) occurs in peripheral tissues several years before the onset of typical motor symptoms. Early and reliable diagnosis of PD could provide new treatment options for PD patients and improve their quality of life. At present, however, diagnosis relies mainly on clinical symptoms, and definitive diagnosis is still based on postmortem pathological confirmation of dopaminergic neuronal degeneration. In addition, the similarity of the clinical, cognitive, and neuropathological features of PD with other neurodegenerative diseases calls for new biomarkers, suitable for differential diagnosis. Alpha-synuclein (α-Syn) is a potential PD biomarker, due to its close connection with the pathogenesis of the disease. Here we summarize the currently available information on the possible use of α-Syn as a biomarker of early stages of PD in gastrointestinal (GI) tissues, highlight its potential to distinguish PD and other neurodegenerative diseases, and suggest alternative methods (primarily developed for other tissue analysis) that could improve α-Syn detection procedures or diagnostic methods in general.

Keywords: LCO; PMCA; Parkinson’s disease; alpha-synuclein; biomarker; gastrointestinal tract; microRNA; oligomeric alpha-synuclein.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Diagnosis, Differential
  • Early Diagnosis
  • Gastrointestinal Tract / metabolism*
  • Humans
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / metabolism*
  • alpha-Synuclein / metabolism*

Substances

  • Biomarkers
  • SNCA protein, human
  • alpha-Synuclein